Mesalazine controlled-release - Allergan

Drug Profile

Mesalazine controlled-release - Allergan

Alternative Names: Asacol HD; Delzicol; Mesalazine controlled-release capsules - Allergan; Mesalazine controlled-release tablets - Allergan; Mesalazine delayed-release capsules - Allergan; Mesalazine delayed-release tablets - Allergan

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer Allergan; Warner Chilcott
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
  • 31 Mar 2013 Launched for Ulcerative colitis (mild to moderately active disease and maintenance of remission) in USA (PO, capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top